MaaT closes in on Europe’s first microbiota therapeutic approval

Shares in MaaT Pharma (Euronext: MAAT), a French microbiome company in oncology, closed 25% higher Tuesday.

The company earlier announced the submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013, under the registered brand name of Xervyteg.

If approved, Xervyteg would become the first microbiota therapeutic approved by the EMA, and the first one globally for a hematology indication. It would also be the first approval for the treatment of acute graft-versus-host disease including gastro-intestinal involvement (GI-aGvHD) following two prior lines of systemic therapy.